Lipocine (NASDAQ:LPCN) Issues Earnings Results

Posted by on Aug 4th, 2026

Lipocine (NASDAQ:LPCN – Get Free Report) announced its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.08, FiscalAI reports. The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.21 million. Lipocine had a negative return on equity of 66.70% and a negative net margin of 571.18%.

Lipocine Trading Up 1.7%

Shares of LPCN stock traded up $0.04 on Tuesday, hitting $2.15. 17,760 shares of the stock were exchanged, compared to its average volume of 228,463. The firm has a market capitalization of $17.68 million, a P/E ratio of -1.14 and a beta of 0.44. Lipocine has a fifty-two week low of $1.81 and a fifty-two week high of $12.37. The business has a 50-day moving average of $2.28 and a 200 day moving average of $4.87.

Hedge Funds Weigh In On Lipocine

A number of large investors have recently bought and sold shares of the company. Citadel Advisors LLC bought a new position in shares of Lipocine during the 3rd quarter worth approximately $41,000. Jane Street Group LLC acquired a new position in Lipocine during the fourth quarter worth $85,000. Renaissance Technologies LLC boosted its holdings in Lipocine by 3.6% during the fourth quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock worth $300,000 after purchasing an additional 1,300 shares during the last quarter. Boothbay Fund Management LLC bought a new position in Lipocine in the fourth quarter valued at $441,000. Finally, Geode Capital Management LLC lifted its position in Lipocine by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock worth $502,000 after buying an additional 1,374 shares in the last quarter. Institutional investors and hedge funds own 9.11% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on LPCN. HC Wainwright reiterated a “neutral” rating on shares of Lipocine in a report on Monday, April 6th. Wall Street Zen upgraded shares of Lipocine from a “sell” rating to a “hold” rating in a report on Saturday, July 18th. Finally, Weiss Ratings lowered shares of Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 18th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $15.00.

Read Our Latest Stock Report on LPCN

Lipocine Company Profile

(Get Free Report)

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.

Read More

Earnings History for Lipocine (NASDAQ:LPCN)

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.